首页> 外文期刊>The American Journal of Human Genetics >Comparing phylogeny and the predicted pathogenicity of protein variations reveals equal purifying selection across the global human mtDNA diversity.
【24h】

Comparing phylogeny and the predicted pathogenicity of protein variations reveals equal purifying selection across the global human mtDNA diversity.

机译:比较系统发生学和预测的蛋白变异致病性,可以发现全球人类mtDNA多样性具有相同的纯化选择。

获取原文
获取原文并翻译 | 示例
       

摘要

We used detailed phylogenetic trees for human mtDNA, combined with pathogenicity predictions for each amino acid change, to evaluate selection on mtDNA-encoded protein variants. Protein variants with high pathogenicity scores were significantly rarer in the older branches of the tree. Variants that have formed and survived multiple times in the human phylogenetics tree had significantly lower pathogenicity scores than those that only appear once in the tree. We compared the distribution of pathogenicity scores observed on the human phylogenetic tree to the distribution of all possible protein variations to define a measure of the effect of selection on these protein variations. The measured effect of selection increased exponentially with increasing pathogenicity score. We found no measurable difference in this measure of purifying selection in mtDNA across the global population, represented by the macrohaplogroups L, M, and N. We provide a list of all possible single amino acid variations for the human mtDNA-encoded proteins with their predicted pathogenicity scores and our measured selection effect as a tool for assessing novel protein variations that are often reported in patients with mitochondrial disease of unknown origin or for assessing somatic mutations acquired through aging or detected in tumors.
机译:我们使用了人类mtDNA的详细系统树,并结合了每个氨基酸变化的致病性预测,以评估mtDNA编码的蛋白质变体的选择。具有较高致病性评分的蛋白质变体在树的较老树枝中非常少见。与仅在树中出现一次的变种相比,在人类系统树中形成并存活多次的变种的致病性得分要低得多。我们将在人类系统树上观察到的致病性得分的分布与所有可能的蛋白质变异的分布进行比较,以定义选择对这些蛋白质变异的影响的度量。选择的测量效果随着致病性评分的增加而呈指数增加。我们发现,在全球人群中,以大单体组L,M和N为代表,在纯化mtDNA的选择纯化方法中没有可测量的差异。致病性评分和我们测得的选择效果,作为评估未知来源的线粒体疾病患者中经常报道的新型蛋白质变异或评估因衰老而获得或在肿瘤中检测到的体细胞突变的工具。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号